Page last updated: 2024-11-01

norfloxacin and Neoplasms

norfloxacin has been researched along with Neoplasms in 12 studies

Norfloxacin: A synthetic fluoroquinolone (FLUOROQUINOLONES) with broad-spectrum antibacterial activity against most gram-negative and gram-positive bacteria. Norfloxacin inhibits bacterial DNA GYRASE.
norfloxacin : A quinolinemonocarboxylic acid with broad-spectrum antibacterial activity against most gram-negative and gram-positive bacteria. Norfloxacin is bactericidal and its mode of action depends on blocking of bacterial DNA replication by binding itself to an enzyme called DNA gyrase.

Neoplasms: New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.

Research Excerpts

ExcerptRelevanceReference
"Sixty-five cancer patients pretreated with chemo or radiotherapy, with granulocytopenia less than 1000/mm3 and without fever, were entered into this study: 30 of them were submitted to prophylaxis with norfloxacin while the remaining 35 patients were used as a control group."6.66Chemoprophylaxis of bacterial infections in granulocytopenic cancer patients using norfloxacin. ( Ameglio, F; Casali, A; Frasca, AM; Gallo Curcio, C; Modugno, G; Paoletti, G; Tonachella, R; Tropea, F; Verri, C, 1988)
"Sixty-five cancer patients pretreated with chemo or radiotherapy, with granulocytopenia less than 1000/mm3 and without fever, were entered into this study: 30 of them were submitted to prophylaxis with norfloxacin while the remaining 35 patients were used as a control group."2.66Chemoprophylaxis of bacterial infections in granulocytopenic cancer patients using norfloxacin. ( Ameglio, F; Casali, A; Frasca, AM; Gallo Curcio, C; Modugno, G; Paoletti, G; Tonachella, R; Tropea, F; Verri, C, 1988)
"The global pandemic of drug-sensitive cancers and the increasing threat from drug-resistant cancers make an urgent need to develop more effective anti-cancer candidates."2.61Quinolone hybrids and their anti-cancer activities: An overview. ( Gao, F; Wang, T; Xiao, J; Zhang, X, 2019)
"Trovafloxacin was also the most active agent tested against Gram-positive organisms, including ciprofloxacin-susceptible strains and most ciprofloxacin- and methicillin-resistant staphylococci and enterococci."1.30In-vitro activity of trovafloxacin against clinical bacterial isolates from patients with cancer. ( Dvorak, T; Ho, DH; LeBlanc, B; Rolston, KV; Streeter, H, 1997)

Research

Studies (12)

TimeframeStudies, this research(%)All Research%
pre-19901 (8.33)18.7374
1990's6 (50.00)18.2507
2000's1 (8.33)29.6817
2010's4 (33.33)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Azéma, J1
Guidetti, B1
Dewelle, J1
Le Calve, B1
Mijatovic, T1
Korolyov, A1
Vaysse, J1
Malet-Martino, M1
Martino, R1
Kiss, R1
Lin, R1
Elf, S1
Shan, C1
Kang, HB1
Ji, Q1
Zhou, L1
Hitosugi, T1
Zhang, L1
Zhang, S1
Seo, JH1
Xie, J1
Tucker, M1
Gu, TL1
Sudderth, J1
Jiang, L1
Mitsche, M1
DeBerardinis, RJ1
Wu, S1
Li, Y1
Mao, H1
Chen, PR1
Wang, D1
Chen, GZ1
Hurwitz, SJ1
Lonial, S1
Arellano, ML1
Khoury, HJ1
Khuri, FR1
Lee, BH1
Lei, Q1
Brat, DJ1
Ye, K1
Boggon, TJ1
He, C1
Kang, S1
Fan, J1
Chen, J1
Chu, XM1
Wang, C1
Liu, W1
Liang, LL1
Gong, KK1
Zhao, CY1
Sun, KL1
Gao, F1
Zhang, X1
Wang, T1
Xiao, J1
Abdelwahab, M1
Salahuddin, N1
Gaber, M1
Mousa, M1
Carratalá, J2
Fernández-Sevilla, A2
Tubau, F2
Callis, M1
Gudiol, F2
Broun, ER1
Wheat, JL1
Kneebone, PH1
Sundblad, K1
Hromas, RA1
Tricot, G1
Del Favero, A1
Menichetti, F1
Dominguez, MA1
Rolston, KV1
Ho, DH1
LeBlanc, B1
Streeter, H1
Dvorak, T1
D'Antonio, D1
Iacone, A1
Fioritoni, G1
Betti, S1
Dell'Isola, M1
Quaglietta, AM1
Accorsi, P1
Pantalone, V1
Recchia, A1
Piergallini, A1
Casali, A1
Verri, C1
Paoletti, G1
Tropea, F1
Modugno, G1
Frasca, AM1
Ameglio, F1
Tonachella, R1
Gallo Curcio, C1

Reviews

3 reviews available for norfloxacin and Neoplasms

ArticleYear
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
    Nature cell biology, 2015, Volume: 17, Issue:11

    Topics: AMP-Activated Protein Kinase Kinases; AMP-Activated Protein Kinases; Humans; Lipogenesis; Neoplasms;

2015
Quinoline and quinolone dimers and their biological activities: An overview.
    European journal of medicinal chemistry, 2019, Jan-01, Volume: 161

    Topics: Anti-Bacterial Agents; Antimalarials; Antineoplastic Agents; Bacteria; Dimerization; Humans; Neoplas

2019
Quinolone hybrids and their anti-cancer activities: An overview.
    European journal of medicinal chemistry, 2019, Mar-01, Volume: 165

    Topics: Animals; Antineoplastic Agents; Humans; Neoplasms; Quinolones; Structure-Activity Relationship

2019

Trials

3 trials available for norfloxacin and Neoplasms

ArticleYear
Randomized trial of the addition of gram-positive prophylaxis to standard antimicrobial prophylaxis for patients undergoing autologous bone marrow transplantation.
    Antimicrobial agents and chemotherapy, 1994, Volume: 38, Issue:3

    Topics: Acyclovir; Adult; Bacteremia; Bone Marrow Transplantation; Female; Fever; Fluconazole; Gram-Positive

1994
Comparison of norfloxacin and pefloxacin in the prophylaxis of bacterial infection in neutropenic cancer patients.
    Drugs under experimental and clinical research, 1992, Volume: 18, Issue:4

    Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Bacteremia; Bacterial Infections; Female; Fever; Hum

1992
Chemoprophylaxis of bacterial infections in granulocytopenic cancer patients using norfloxacin.
    Chemioterapia : international journal of the Mediterranean Society of Chemotherapy, 1988, Volume: 7, Issue:5

    Topics: Agranulocytosis; Bacterial Infections; Clinical Trials as Topic; Drug Evaluation; Humans; Neoplasms;

1988

Other Studies

6 other studies available for norfloxacin and Neoplasms

ArticleYear
7-((4-Substituted)piperazin-1-yl) derivatives of ciprofloxacin: synthesis and in vitro biological evaluation as potential antitumor agents.
    Bioorganic & medicinal chemistry, 2009, Aug-01, Volume: 17, Issue:15

    Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Ciprofloxacin; Humans; Maximum

2009
Poly(3-hydroxybutyrate)/polyethylene glycol-NiO nanocomposite for NOR delivery: Antibacterial activity and cytotoxic effect against cancer cell lines.
    International journal of biological macromolecules, 2018, Jul-15, Volume: 114

    Topics: Anti-Bacterial Agents; Bacteria; Cell Line, Tumor; Cytotoxins; Drug Delivery Systems; Humans; Nanoco

2018
Emergence of quinolone-resistant Escherichia coli bacteremia in neutropenic patients with cancer who have received prophylactic norfloxacin.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 1995, Volume: 20, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Bacteremia; Drug Resistance, Microbial; Escherichia coli Infections;

1995
The new fluorinated quinolones for antimicrobial prophylaxis in neutropenic cancer patients.
    European journal of cancer (Oxford, England : 1990), 1993, Volume: 29A Suppl 1

    Topics: Anti-Bacterial Agents; Anti-Infective Agents; Ciprofloxacin; Drug Therapy, Combination; Gram-Negativ

1993
Emergence of fluoroquinolone-resistant Escherichia coli in fecal flora of cancer patients receiving norfloxacin prophylaxis.
    Antimicrobial agents and chemotherapy, 1996, Volume: 40, Issue:2

    Topics: Acute Disease; Adolescent; Adult; Aged; Anti-Infective Agents; DNA, Bacterial; Drug Resistance, Micr

1996
In-vitro activity of trovafloxacin against clinical bacterial isolates from patients with cancer.
    The Journal of antimicrobial chemotherapy, 1997, Volume: 39 Suppl B

    Topics: Anti-Infective Agents; Ciprofloxacin; Fluoroquinolones; Gram-Negative Bacteria; Gram-Positive Bacter

1997